Clinical Trial Update: Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial updates on Campath and calcineurin inhibitor reduction for chronic allograft nephropathy in kidney transplantation have completed phase 2/3 with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: University of Oxford | Conditions: Kidney Transplantation | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-10-01